Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22310%2F16%3A43902603" target="_blank" >RIV/60461373:22310/16:43902603 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1007/s00213-015-4119-3" target="_blank" >http://dx.doi.org/10.1007/s00213-015-4119-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00213-015-4119-3" target="_blank" >10.1007/s00213-015-4119-3</a>

Result language

angličtina

Original language name

Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens

Original language description

Rationale and objectives: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). Methods: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. Results: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. Conclusions: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

<a href="/en/project/LO1215" target="_blank" >LO1215: Prague University Analytical Center for Health, Food Safety and Environmental Protection</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Psychopharmacology

ISSN

1432-2072

e-ISSN

—

Volume of the periodical

233

Issue of the periodical within the volume

3

Country of publishing house

DE - GERMANY

Number of pages

16

Pages from-to

469-484

UT code for WoS article

—

EID of the result in the Scopus database

—